FM
fazen.markets
healthcare·esfritzh

Theriva Biologics Sets 1-for-30 Reverse Split, TOVX Eyes NYSE Rule

23h ago|5 min read2Standard
FM

Fazen Markets

Source: SEC EDGAR

Written by AI from a primary source ·

theriva-biologicsreverse-stock-splittovxnyse-americanclinical-stage-biotech

Key Takeaways

  • 1Theriva's 1-for-30 reverse split is a listing-compliance fix that shrinks the share count to about 1,529,756 without changing the business.

Partner

Trade the Markets Discussed in This Article

Regulated Broker Competitive Spreads

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Theriva Biologics, Inc. (NYSE American: TOVX) announced on 20 November 2026 that its board authorized a 1-for-30 reverse stock split, effective 11:59 p.m. Eastern Time on 1 December 2026. Outstanding shares fall from 45,892,668 to roughly 1,529,756, and authorized shares drop from 350,000,000 to 11,666,666. TOVX begins trading split-adjusted at the open on 2 December 2026 under a new CUSIP, 87164U607, while keeping its existing ticker.

Context — why the reverse split matters now

The company tied the move to a specific obligation: the split is being effected "to ensure that the Company can meet the per share price requirements of the NYSE American," its current listing exchange. That is the stated catalyst, and it is the only one the company gives.

NYSE American maintains minimum per-share price standards for continued listing. A stock that trades below that threshold for a sustained period can be delisted. The reverse split mechanically multiplies the quoted price by thirty while leaving the underlying business untouched.

The board authorized the split on 13 November 2026, seven days before the public announcement. Theriva incorporated in Nevada, and under Nevada law the board can complete a reverse split without shareholder approval when authorized shares and outstanding shares are cut proportionally. That condition is met here.

The company will file a certificate of change to its amended articles of incorporation with the Nevada Secretary of State. No shareholder vote is required or scheduled, so there is no proxy timeline for investors to track.

Theriva describes itself as a diversified clinical-stage company developing therapeutics for cancer and related diseases in areas of high unmet need. Its lead candidate, VCN-01 (zabilugene almadenorepvec), is an oncolytic adenovirus designed to replicate selectively inside tumor cells and degrade the tumor stroma barrier. The company said the platform is designed for intravenous, intravitreal and intratumoral delivery.

The split changes the share count, not the science. Investors scanning healthcare coverage should read the event as a listing-compliance action rather than a clinical or financing update.

Data — what the numbers show

The arithmetic is the story. Before the effective date the company has 45,892,668 shares outstanding and 350,000,000 authorized. After the proportional reduction it has approximately 1,529,756 shares outstanding and 11,666,666 authorized — a 30-to-1 cut on both lines.

MeasurePre-splitPost-split
Shares outstanding45,892,668~1,529,756
Shares authorized350,000,00011,666,666
Ratio30 shares1 share

The outstanding figure excludes fractional shares. Theriva said no fractional shares will be issued. Any holder whose position is not evenly divisible by thirty will automatically receive an extra fractional share rounded up to the next whole share.

Proportionate adjustments apply to the number of shares issuable on exercise of outstanding warrants and stock options, to the exercise prices of those instruments, and to the shares reserved under the company's equity incentive plans. The company did not disclose the resulting exercise prices or the size of the reserve.

The split takes effect at 11:59 p.m. Eastern Time on 1 December 2026, and split-adjusted trading starts at the open on 2 December 2026. The ticker stays TOVX. The CUSIP changes to 87164U607.

Analysis — what it means for TOVX holders and peers

The immediate mechanical effect is cosmetic. A holder of 30 pre-split shares owns one post-split share of the same company, with the same claim on earnings and the same clinical pipeline. Market capitalization is unchanged by the ratio itself.

The second-order effect is on the listing. Clearing the NYSE American price test removes the most visible near-term delisting trigger, which matters for index eligibility, brokerage display rules and institutional mandates that bar sub-threshold names. That is the benefit the company is buying.

The counter-argument is dilution optics. Reverse splits shrink the share count but do not raise cash, and the company disclosed no concurrent financing alongside the move. A higher quoted price with a thin float can also widen percentage moves on modest volume, since roughly 1.53 million shares will be outstanding.

Round-up treatment of fractional shares is a small, deliberate giveaway: holders with odd lots get a full extra share rather than cash in lieu. On a base near 1.53 million shares, that treatment marginally raises the final count above the stated figure.

Positioning is straightforward. Existing holders see their share count divided by thirty and their per-share price multiplied by the same factor. Warrants and options are adjusted proportionally, so derivative holders face the same economic terms. Anyone trading the event on the assumption of a fundamental change is trading the wrong variable. For broader equities coverage of small-cap listing actions, the compliance angle is the one that travels.

The company did not disclose the pre-split trading price, the specific NYSE American threshold it was failing to meet, or any deadline imposed by the exchange.

Outlook — what to watch next

Two dates carry the event. The split becomes effective at 11:59 p.m. Eastern Time on 1 December 2026, and TOVX begins trading on a split-adjusted basis at the open on 2 December 2026. Until then, quotes reflect the pre-split structure.

After 2 December, the first meaningful signal is whether the adjusted price holds above the NYSE American per-share requirement. The company has not published the threshold, so the level to watch is the exchange's own rule rather than a figure Theriva supplied.

The second signal is the share count itself. Theriva will file a certificate of change with the Nevada Secretary of State, and the final outstanding figure should land near 1,529,756 before fractional round-ups. Any material divergence from that number would point to adjustments in the warrant, option or equity-plan lines the company said would be made proportionately.

Third, watch for any subsequent financing. The report contains none, and a reverse split is frequently followed by capital-raising news in small-cap biotech. Theriva has not signaled one.

Frequently Asked Questions

What does a 1-for-30 reverse stock split mean for retail investors holding TOVX?

Every thirty pre-split shares combine into one new share automatically, with no action required from holders. Investors holding shares in brokerage accounts or street name do not need to exchange certificates; Equiniti Trust Company, the transfer agent and exchange agent, will send instructions only to holders of physical stock certificates. Fractional positions round up to the next whole share.

Why is Theriva Biologics doing a reverse split instead of a buyback or tender?

The company stated the split is being effected to ensure it can meet the per share price requirements of the NYSE American, its current listing exchange. A buyback or tender would require cash the company did not announce. The reverse split raises the quoted price without spending capital, which is why it is the tool used for price-based listing compliance.

Will the reverse split change Theriva's market value or the ticker?

The ticker stays TOVX on the NYSE American, but the CUSIP changes to 87164U607. Market capitalization is not changed by the ratio: the share count falls from 45,892,668 to roughly 1,529,756 while each share represents thirty times as much of the company. Warrants, options and equity-plan reserves are adjusted proportionally.

Bottom Line

Theriva's 1-for-30 reverse split is a listing-compliance fix that shrinks the share count to about 1,529,756 without changing the business.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.

PartnerPosition yourself for the macro moves discussed above

Start Trading
Share

Stay informed

Get market analysis delivered to your inbox.

Join 18,500+ investors

Sponsored

Ready to trade the markets?

Open a demo account in 30 seconds. No deposit required.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Related